<DOC>
	<DOC>NCT00450190</DOC>
	<brief_summary>The aim of the study is to evaluate the E-Device performances and handling on the use in common practice, by collecting the impressions of patients, nurses and the investigator on the graphic interface, the instructions manual, the E-Device training and the material itself.</brief_summary>
	<brief_title>Saizen® E-Device User Trial</brief_title>
	<detailed_description />
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>1. Patients naïve to, or experienced with, Saizen® with growth disorders in registered indications (GHD, Turner's Syndrome, Chronic Renal Failure, patient born SGA according to the local SmPC) 2. Written informed consent must be obtained from the parent(s)/legal guardian(s) at the beginning of the study. Children able to understand the trial should personally sign and date the written informed consent 1. Known hypersensitivity to somatropin or any of the excipients 2. Epiphyseal fusion 3. Active neoplasia (either newly diagnosed or recurrent) 4. History of intracranial hypertension with papilledema 5. Diabetes mellitus or history of significant glucose intolerance as defined by a fasting blood glucose &gt; 116 mg/dL 6. Severe congenital malformations 7. Severe psychomotor retardation 8. Known hepatic disease as defined by elevated liver enzymes or total bilirubin (x 2 N) 9. Current congestive heart failure, untreated hypertension, serious chronic oedema of any cause 10. Chronic infectious disease 11. Previous or ongoing treatment with sex steroid therapy such as estrogens and testosterone 12. Previous or ongoing treatment with any therapy that may directly influence growth, including GH, GHRF and long duration corticosteroids therapy 13. Proliferative or preproliferative diabetic retinopathy 14. Evidence of any progression or recurrence of an underlying intracranial space occupying lesion 15. Precocious puberty 16. Severe associated pathology affecting growth such as malnutrition, malabsorption or bone dysplasia 17. Concomitant corticoid treatment or levothyroxine treatment other than substitutive treatment, topical or inhaled treatment 18. Participation to any clinical study within the 30 days preceding study entry 19. Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Growth disorders/drug therapy</keyword>
</DOC>